Elicera Therapeutics
6.25
SEK
+0.48 %
Less than 1K followers
ELIC
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
+0.48%
+47.41%
+164.83%
+274.25%
+240.6%
+543%
+61.5%
-
+0.81%
Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.
Read moreMarket cap
303.35M SEK
Turnover
1.16M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
29.8
2025
Interim report Q2'25
14.11
2025
Interim report Q3'25
13.2
2026
Annual report '25
All
Research
Press releases
3rd party
ShowingAll content types
Elicera Therapeutics enters a Material Transfer Agreement with University Hospital Tübingen for testing of the company's oncolytic virus candidates, ELC-100 and ELC-201
BioStock: Promising preliminary results for Elicera Therapeutics’ CAR T-cell stud
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools